Date published: 2026-5-18

1-800-457-3801

SCBT Portrait Logo
Seach Input

C20orf152 Activators

Cyclic nucleotide binding domain-containing protein 2 (CNBD2) is a member of the cyclic nucleotide-binding domain (CNBD) family of proteins, characterized by their ability to bind cyclic nucleotides such as cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). These molecules act as second messengers in various signal transduction pathways, translating extracellular signals into a cellular response.The CNBD2 protein, specifically, possesses a domain that is structured to recognize and bind these cyclic nucleotides, leading to a conformational change that typically activates the protein. This activation can have a wide range of downstream effects, depending on the cellular context and the signaling pathways involved. Through its nucleotide-binding capacity, CNBD2 can influence processes such as ion channel regulation, gene transcription, and metabolic regulation.

The particular role of CNBD2 in physiological processes is less well-defined compared to other, more extensively studied CNBD proteins. However, it is hypothesized to be involved in neuronal signaling, given the importance of cyclic nucleotide signaling in the nervous system for functions such as synaptic transmission, plasticity, and neuroprotection. CNBD2 could also have roles in cardiac function, as cAMP and cGMP signaling are critical for regulating heart rate and contractility.

SEE ALSO...

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

IBMX

28822-58-4sc-201188
sc-201188B
sc-201188A
200 mg
500 mg
1 g
$260.00
$350.00
$500.00
34
(1)

IBMX is a non-selective inhibitor of phosphodiesterases, leading to increased levels of cAMP and cGMP, which may indirectly affect CNBD2.

Cilostazol

73963-72-1sc-201182
sc-201182A
10 mg
50 mg
$109.00
$322.00
3
(1)

Cilostazol inhibits phosphodiesterase type 3, increasing cAMP levels, which might impact CNBD2 activity.

Dipyridamole

58-32-2sc-200717
sc-200717A
1 g
5 g
$31.00
$102.00
1
(1)

Dipyridamole inhibits phosphodiesterase and increases cAMP and cGMP levels, potentially affecting CNBD2.

Rolipram

61413-54-5sc-3563
sc-3563A
5 mg
50 mg
$77.00
$216.00
18
(1)

Rolipram selectively inhibits phosphodiesterase type 4, leading to increased cAMP levels, possibly influencing CNBD2.

BAY 41-2272

256376-24-6sc-202491
sc-202491A
5 mg
25 mg
$238.00
$728.00
4
(0)

BAY 41-2272 activates soluble guanylate cyclase, increasing cGMP levels, potentially impacting CNBD2.

Riociguat

625115-55-1sc-476845
5 mg
$300.00
(0)

Riociguat stimulates soluble guanylate cyclase, increasing cGMP levels, and might influence CNBD2.

Adenosine

58-61-7sc-291838
sc-291838A
sc-291838B
sc-291838C
sc-291838D
sc-291838E
sc-291838F
1 g
5 g
100 g
250 g
1 kg
5 kg
10 kg
$34.00
$48.00
$300.00
$572.00
$1040.00
$2601.00
$4682.00
1
(0)

Adenosine can modulate adenylate cyclase activity, potentially influencing cAMP levels and thereby CNBD2.

Milrinone

78415-72-2sc-201193
sc-201193A
10 mg
50 mg
$165.00
$697.00
7
(0)

Milrinone inhibits phosphodiesterase type 3, increasing cAMP levels, potentially impacting CNBD2.